/C O R R E C T I O N -- Johnson & Johnson/
PR Newswire —
In the news release, Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE), issued 03-Mar-2026 by Johnson & Johnson over PR Newswire, we are advised by the company that the last sentence of the fifth paragraph has been amended....